Global research and current trends on nanotherapy in lung cancer research: a bibliometric analysis of 20 years.
Bibliometric analysis
Lung cancer research
Nanomaterials
Scopus database
Journal
Discover oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
21
05
2024
accepted:
10
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
epublish
Résumé
Lung cancer ranks as one of the most rapidly growing malignancies. Which is characterized by its poor prognosis and a low survival rate due to late diagnosis and limited efficacy of conventional treatments. In recent years nanotechnology has emerged as a promising frontier in the management of lung cancer, presenting novel strategies to enhance drug administration, improve therapeutic efficiency, and mitigate side effects. This research comprehensively evaluates the current state and research trends concerning the application of nanomaterials in lung cancer through bibliometric analysis. We employed a systematic approach by retrieving studies from the Scopus database that focused on nanomaterials and lung cancer between 2003 and 2023. Subsequently, we carefully selected relevant articles based on predetermined inclusion criteria. The selected publications were then subjected to bibliometric and visual analysis using softwares such as VOSviewer and Biblioshiny. A total of 3523 studies that meet inclusion criteria were selected for bibliometric analysis. We observed a progressive increase in the number of annual publications from 2003 to 2023, indicating the growing interest in this field. According to our analysis, China is the primary contributor to publication output among the countries. The "Ministry of Education of the People's Republic of China" was the most influential institution. Among the authors, "Dr. Jack A. Roth" and "Dr. Huang Leaf" had the highest number of publications and cited publications, respectively. The "International Journal of Nanomedicine" was found to be the most prolific journal in this field. Additionally, "Biomaterials" emerged as the most cited journal. Through keyword analysis, we identified five main research themes and future research directions; nono-immunotherapy and green synthesis are the hot topics in this research field. Our study summarized the key characteristics of publications in this field and identified the most influential countries, institutions, authors, journals, hot topics, and trends related to the application of nanomaterials in lung cancer. These findings contribute to the existing body of knowledge and serve as a foundation for future research endeavors in this area. More effective efforts are needed in this field to reduce the burden of lung cancer and help achieve the United Nation's Sustainable Development Goals.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer ranks as one of the most rapidly growing malignancies. Which is characterized by its poor prognosis and a low survival rate due to late diagnosis and limited efficacy of conventional treatments. In recent years nanotechnology has emerged as a promising frontier in the management of lung cancer, presenting novel strategies to enhance drug administration, improve therapeutic efficiency, and mitigate side effects. This research comprehensively evaluates the current state and research trends concerning the application of nanomaterials in lung cancer through bibliometric analysis.
MATERIALS AND METHODS
METHODS
We employed a systematic approach by retrieving studies from the Scopus database that focused on nanomaterials and lung cancer between 2003 and 2023. Subsequently, we carefully selected relevant articles based on predetermined inclusion criteria. The selected publications were then subjected to bibliometric and visual analysis using softwares such as VOSviewer and Biblioshiny.
RESULTS
RESULTS
A total of 3523 studies that meet inclusion criteria were selected for bibliometric analysis. We observed a progressive increase in the number of annual publications from 2003 to 2023, indicating the growing interest in this field. According to our analysis, China is the primary contributor to publication output among the countries. The "Ministry of Education of the People's Republic of China" was the most influential institution. Among the authors, "Dr. Jack A. Roth" and "Dr. Huang Leaf" had the highest number of publications and cited publications, respectively. The "International Journal of Nanomedicine" was found to be the most prolific journal in this field. Additionally, "Biomaterials" emerged as the most cited journal. Through keyword analysis, we identified five main research themes and future research directions; nono-immunotherapy and green synthesis are the hot topics in this research field.
CONCLUSION
CONCLUSIONS
Our study summarized the key characteristics of publications in this field and identified the most influential countries, institutions, authors, journals, hot topics, and trends related to the application of nanomaterials in lung cancer. These findings contribute to the existing body of knowledge and serve as a foundation for future research endeavors in this area. More effective efforts are needed in this field to reduce the burden of lung cancer and help achieve the United Nation's Sustainable Development Goals.
Identifiants
pubmed: 39384612
doi: 10.1007/s12672-024-01332-2
pii: 10.1007/s12672-024-01332-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
539Informations de copyright
© 2024. The Author(s).
Références
Chiang C-L, Cheng M-H, Lin C-H. From nanoparticles to cancer nanomedicine: old problems with new solutions. Nanomaterials. 2021;11:1727.
doi: 10.3390/nano11071727
Feng Q, Zhang H, Dong Z, Zhou Y, Ma J. Circulating 25-hydroxyvitamin D and lung cancer risk and survival: a dose–response meta-analysis of prospective cohort studies. Medicine. 2017;96: e8613.
doi: 10.1097/MD.0000000000008613
Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, Siegel RL. Lung cancer statistics, 2023. Cancer. 2024;130:1330–48.
doi: 10.1002/cncr.35128
Wang J, Zhou T, Liu Y, Chen S, Yu Z. Application of nanoparticles in the treatment of lung cancer with emphasis on receptors. Front Pharmacol. 2022;10(12): 781425.
doi: 10.3389/fphar.2021.781425
Khanmohammadi A, Aghaie A, Vahedi E, Qazvini A, Ghanei M, Afkhami A, Hajian A, Bagheri H. Electrochemical biosensors for the detection of lung cancer biomarkers: a review. Talanta. 2020;1(206): 120251.
doi: 10.1016/j.talanta.2019.120251
Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, Singh SK, Chellappan DK, Gupta G, Prasher P, Dua K. Advances in lung cancer treatment using nanomedicines. ACS Omega. 2022;8(1):10–41.
doi: 10.1021/acsomega.2c04078
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288.
doi: 10.21037/tlcr.2016.06.07
Bakx R, Emous M, Legemate D, Zoetmulder F, van Tienhoven G, Bemelman W, van Lanschot J. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006;32:520–6.
doi: 10.1016/j.ejso.2006.02.023
Guo J, Liu H, Zheng J. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. Nucleic Acids Res. 2016;44(D1):D1011–7.
doi: 10.1093/nar/gkv1108
Jiang Q, Yu L, Chen Y. Engineering self-assembled nanomedicines composed of clinically approved medicines for enhanced tumor nanotherapy. Nanomaterials. 2023;13(18):2499.
doi: 10.3390/nano13182499
Shen Y, Li M, Liu T, Liu J, Xie Y, Zhang J, Xu S, Liu H. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. Int J Nanomed. 2019;14:4029–44.
doi: 10.2147/IJN.S201688
Dang Y, Guan J. Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med. 2020;1:10–9.
doi: 10.1016/j.smaim.2020.04.001
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Can Res. 1994;54(4):987–92.
Jain S, Hirst D, O’Sullivan J. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101–13.
doi: 10.1259/bjr/59448833
Rajeshkumar S. Anticancer activity of eco-friendly gold nanoparticles against lung and liver cancer cells. J Genetic Eng Biotechnol. 2016;14(1):195–202.
doi: 10.1016/j.jgeb.2016.05.007
Vines JB, Yoon J-H, Ryu N-E, Lim D-J, Park H. Gold nanoparticles for photothermal cancer therapy. Front Chem. 2019;7:167.
doi: 10.3389/fchem.2019.00167
Chen F, Hableel G, Zhao ER, Jokerst JV. Multifunctional nanomedicine with silica: role of silica in nanoparticles for theranostic, imaging, and drug monitoring. J Colloid Interface Sci. 2018;521:261–79.
doi: 10.1016/j.jcis.2018.02.053
Howell M, Wang C, Mahmoud A, Hellermann G, Mohapatra SS, Mohapatra S. Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Deliv Transl Res. 2013;3:352–63.
doi: 10.1007/s13346-013-0132-4
Jain KK. Drug delivery systems—an overview. In: Jain KK, editor. Drug delivery systems. New York: Humana Press; 2008. https://doi.org/10.1007/978-1-59745-210-6 .
doi: 10.1007/978-1-59745-210-6
Abaszadeh F, Ashoub MH, Khajouie G, Amiri M. Nanotechnology development in surgical applications: recent trends and developments. Eur J Med Res. 2023;28(1):537.
doi: 10.1186/s40001-023-01429-4
Babu A, Templeton AK, Munshi A, Ramesh R. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. 2013;2013: 863951.
doi: 10.1155/2013/863951
Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105:1809–31.
doi: 10.1007/s11192-015-1645-z
Belter CW. Bibliometric indicators: opportunities and limits. J Med Libr Assoc. 2015;103(4):219.
doi: 10.3163/1536-5050.103.4.014
Møller A, Myles P. What makes a good systematic review and meta-analysis? Br J Anaesthesia. 2016;117(4):428–30.
doi: 10.1093/bja/aew264
Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of pubmed, scopus, web of science, and google scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–42.
doi: 10.1096/fj.07-9492LSF
Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in web of science, scopus, and google scholar for articles published in general medical journals. JAMA. 2009;302(10):1092–6.
doi: 10.1001/jama.2009.1307
Agarwal A, Durairajanayagam D, Tatagari S, Esteves SC, Harlev A, Henkel R, et al. Bibliometrics: tracking research impact by selecting the appropriate metrics. Asian J Androl. 2016;18(2):296.
doi: 10.4103/1008-682X.171582
Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci. 2005;102(46):16569–72.
doi: 10.1073/pnas.0507655102
Aghaei Chadegani A, Salehi H, Md Yunus M, Farhadi H, Fooladi M, Farhadi M, Ale Ebrahim N. A comparison between two main academic literature collections: web of science and scopus databases. Asian Soc Sci. 2013;9(5):18–26.
Musa IH, Afolabi LO, Zamit I, Musa TH, Musa HH, Tassang A, Akintunde TY, Li W. Artificial intelligence and machine learning in cancer research: a systematic and thematic analysis of the top 100 cited articles indexed in Scopus database. Cancer Control. 2022;29:10732748221095946.
doi: 10.1177/10732748221095946
AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. J Vis Exp. 2019;152: e58494.
He J, Wu W. Comprehensive landscape and future perspectives of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC): Based on a bibliometric analysis. Non-coding RNA Res. 2023;8(1):33–52.
doi: 10.1016/j.ncrna.2022.10.001
Lin L, Liang L, Wang M, Huang R, Gong M, Song G, Hao T. A bibliometric analysis of worldwide cancer research using machine learning methods. Cancer Innov. 2023;2(3):219–32. https://doi.org/10.1002/cai2.68 .
doi: 10.1002/cai2.68
Semwal P, Singh P, Gargi B, Trivedi V, Thapliyal A. Global research progress on reproductive behavior and ethnobotany of the Saussurea genus: literature review-based-bibliometric analysis. Ethnobot Res Appl. 2023;26:1–15.
Singh P, Gargi B, Semwal P, Mishra J, Thapliyal A. Global research trends, publication characteristics and knowledge domains of plant reproductive biology: a bibliometric and knowledge mapping analysis of 50 years. Ecol Front. 2023;44(3):451–8. https://doi.org/10.1016/j.chnaes.2023.08.010 .
doi: 10.1016/j.chnaes.2023.08.010
Alcantara JH, Ornos EDB, Tantengco OAG. Global trends, gaps, and future agenda in medulloblastoma research: a bibliometric analysis. Childs Nerv Syst. 2023;39:3185–94. https://doi.org/10.1007/s00381-023-05969-2 .
doi: 10.1007/s00381-023-05969-2
Jiang S, Liu Y, Zheng H, Zhang L, Zhao H, Sang X, et al. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg. 2023;109(9):2774–83. https://doi.org/10.1097/js9.0000000000000492 .
doi: 10.1097/js9.0000000000000492
Liu Y, Cheng X, Han X, Cheng X, Jiang S, Lin Y, Zhang Z, Lu L, Qu B, Chen Y. Global research landscape and trends of lung cancer immunotherapy: a bibliometric analysis. Front Immunol. 2022;13:1032747.
doi: 10.3389/fimmu.2022.1032747
Van Eck N, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.
doi: 10.1007/s11192-009-0146-3
Wang S, Zhang L, Jin Z, Wang Y, Zhang B, Zhao L. Visualizing temporal dynamics and research trends of macrophage-related diabetes studies between 2000 and 2022: a bibliometric analysis. Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1194738 .
doi: 10.3389/fimmu.2023.1194738
Lin W, Huang YW, Zhou XD, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006;217(3):252–9.
doi: 10.1016/j.taap.2006.10.004
Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 2009;4(10):669–73.
doi: 10.1038/nnano.2009.235
Karlsson HL, Gustafsson J, Cronholm P, Möller L. Size-dependent toxicity of metal oxide particles—a comparison between nano-and micrometer size. Toxicol Lett. 2009;188(2):112–8.
doi: 10.1016/j.toxlet.2009.03.014
Peng G, Hakim M, Broza Y, Billan S, Abdah-Bortnyak R, Kuten A, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103(4):542–51.
doi: 10.1038/sj.bjc.6605810
Durán-Acevedo CM, Jaimes-Mogollón AL, Gualdrón-Guerrero OE, Welearegay TG, Martinez-Marín JD, Caceres-Tarazona JM, et al. Exhaled breath analysis for gastric cancer diagnosis in Colombian patients. Oncotarget. 2018;9(48):28805.
doi: 10.18632/oncotarget.25331
Sakumura Y, Koyama Y, Tokutake H, Hida T, Sato K, Itoh T, et al. Diagnosis by volatile organic compounds in exhaled breath from lung cancer patients using support vector machine algorithm. Sensors. 2017;17(2):287.
doi: 10.3390/s17020287
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.
doi: 10.3389/fmolb.2020.00193
Wang K, Zhang H, Li X, Ding Y, Li J, Wang Z, et al. Bibliometric analysis of global research trends on small-cell lung cancer (2012–2021). Front Oncol. 2022;12: 955259.
doi: 10.3389/fonc.2022.955259
Chen H, Lai Y, Ye C, Wu C, Zhang J, Zhang Z, Yao Q. Global research trends between gut microbiota and lung cancer from 2011 to 2022: a bibliometric and visualization analysis. Front Oncol. 2023;13:1137576.
doi: 10.3389/fonc.2023.1137576
Liu Y, Jiang S, Lin Y, Yu H, Yu L, Zhang X. Research landscape and trends of lung cancer radiotherapy: a bibliometric analysis. Front Oncol. 2022;12:1066557.
doi: 10.3389/fonc.2022.1066557
Liu Y, Cheng X, Han X, Cheng X, Jiang S, Lin Y, et al. Global research landscape and trends of lung cancer immunotherapy: a bibliometric analysis. Front Immunol. 2022;13:1032747.
doi: 10.3389/fimmu.2022.1032747
Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(05):584–90.
doi: 10.1097/CM9.0000000000002108
Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res. 2021;133:285–96. https://doi.org/10.1016/j.jbusres.2021.04.070 .
doi: 10.1016/j.jbusres.2021.04.070
Jeevanandam J, Kiew SF, Boakye-Ansah S, Lau SY, Barhoum A, Danquah MK, Rodrigues J. Green approaches for the synthesis of metal and metal oxide nanoparticles using microbial and plant extracts. Nanoscale. 2022;14(7):2534–71.
doi: 10.1039/D1NR08144F
Jain N, Jain P, Rajput D, Patil UK. Green synthesized plant-based silver nanoparticles. Therapeutic prospective for anticancer and antiviral activity. Micro Nano Syst Lett. 2021;9(1):5.
doi: 10.1186/s40486-021-00131-6
Sasaki D, Kusamori K, Takayama Y, Itakura S, Todo H, Nishikawa M. Development of nanoparticles derived from corn as mass producible bionanoparticles with anticancer activity. Sci Rep. 2021;11(1):22818.
doi: 10.1038/s41598-021-02241-y
Al-Hujaily EM, Khatlani T, Alehaideb Z, Ali R, Almuzaini B, Alrfaei BM, et al. Therapeutics discovery: from bench to first in-human trials. Biomed Rep. 2018;8(3):275–82.
Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother. 2019;20(1):95–102.
doi: 10.1080/14656566.2018.1546290
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.
doi: 10.1056/NEJMoa1810865
Mohapatra S, Rout SR, Narayan R, Maiti TK. Multifunctional mesoporous hollow silica nanocapsules for targeted co-delivery of cisplatin-pemetrexed and MR imaging. Dalton Trans. 2014;43(42):15841–50.
doi: 10.1039/C4DT02144D
Chen H, Sun X, Wang GD, Nagata K, Hao Z, Wang A, et al. LiGa 5 O 8: Cr-based theranostic nanoparticles for imaging-guided X-ray induced photodynamic therapy of deep-seated tumors. Mater Horiz. 2017;4(6):1092–101.
doi: 10.1039/C7MH00442G
Gao M, Su H, Lin G, Li S, Yu X, Qin A, et al. Targeted imaging of EGFR overexpressed cancer cells by brightly fluorescent nanoparticles conjugated with cetuximab. Nanoscale. 2016;8(32):15027–32.
doi: 10.1039/C6NR04439E
Kimura A, Utsumi S, Shimokawa A, Nishimori R, Hosoi R, Stewart NJ, et al. Targeted imaging of lung cancer with hyperpolarized 129Xe MRI using surface-modified iron oxide nanoparticles as molecular contrast agents. Cancers. 2022;14(24):6070.
doi: 10.3390/cancers14246070
Su M, Chen Y, Jia L, Zhang Z. Camptothecin-loaded and manganese dioxide-coated polydopamine nanomedicine used for magnetic resonance imaging diagnosis and chemo-photothermal therapy for lung cancer. Int J Nanomed. 2022;17:6687–705.
doi: 10.2147/IJN.S359300
Huang T, Li S, Fang J, Li F, Tu S. Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy. Bioactive Materials. 2021;6(7):2158–72.
doi: 10.1016/j.bioactmat.2020.12.023
Su W-P, Chang L-C, Song W-H, Yang L-X, Wang L-C, Chia Z-C, et al. Polyaniline-based glyco-condensation on Au nanoparticles enhances immunotherapy in lung cancer. ACS Appl Mater Interfaces. 2022;14(21):24144–59.
doi: 10.1021/acsami.2c03839
Dua K, Shukla SD, de Jesus Andreoli Pinto T, Hansbro PM. Nanotechnology: Advancing the translational respiratory research. Interv Med Appl Sci. 2017;9(1):39–41.
Conti DS, Bharatwaj B, Brewer D, da Rocha SR. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J Control Release. 2012;157(3):406–17.
doi: 10.1016/j.jconrel.2011.09.089
Parvathaneni V, Kulkarni NS, Chauhan G, Shukla SK, Elbatanony R, Patel B, et al. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy–repurposing amodiaquine for non-small cell lung cancer (NSCLC). Mater Sci Eng C. 2020;115: 111139.
doi: 10.1016/j.msec.2020.111139
Dessale M, Mengistu G, Mengist HM. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis. Int J Nanomed. 2022;17:3735.
doi: 10.2147/IJN.S378074
García-Domínguez DJ, López-Enríquez S, Alba G, Garnacho C, Jiménez-Cortegana C, Flores-Campos R, de la Cruz-Merino L, Hajji N, Sánchez-Margalet V, Hontecillas-Prieto L. Cancer nano-immunotherapy: the novel and promising weapon to fight cancer. Int J Mol Sci. 2024;25(2):1195.
doi: 10.3390/ijms25021195
Ribeiro JJK, da Silva Porto PS, Pereira RD, Muniz EP. Green synthesis of nanomaterials: most cited papers and research trends. Res Soc Dev. 2020;9(1):e54911593–e54911593.
doi: 10.33448/rsd-v9i1.1593
Larayetan R, Olisah C, Idris OA. Research progression on studies related to green synthesis nanoparticles: a bibliometric review. In: Saquib Q, Faisal M, Al-Khedhairy AA, Alatar AA, editors. Green synthesis of nanoparticles: applications and prospects. Singapore: Springer; 2020. p. 1–22.
Vadakkan K, Rumjit NP, Ngangbam AK, Vijayanand S, Nedumpillil NK. Novel advancements in the sustainable green synthesis approach of silver nanoparticles (AgNPs) for antibacterial therapeutic applications. Coord Chem Rev. 2024;15(499): 215528.
doi: 10.1016/j.ccr.2023.215528
Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11(11):986–94.
doi: 10.1038/nnano.2016.168
Danhier F, Le Breton A, Préat VR. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9(11):2961–73.
doi: 10.1021/mp3002733
Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132(13):4678–84.
doi: 10.1021/ja908117a
Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85:743–50.
doi: 10.1007/s00204-010-0545-5
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180–8. https://doi.org/10.1007/s10637-016-0407-y .
doi: 10.1007/s10637-016-0407-y